Immunotherapy for Squamous Non-Small Cell Lung Cancer

0 Views
administrator
administrator
07/14/23

http://cancerGRACE.org/

The immune checkpoint inhibitor nivolumab has been shown in the CheckMate 017 trial to lead to better response rates, survival, and better tolerability than docetaxel (Taxotere) chemotherapy. But can we predict which patients will do best?

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next